# A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

> **NCT04800315** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 221 (actual)

## Conditions studied

- Dermatitis, Atopic
- Eczema

## Interventions

- **DRUG:** CC-93538
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04800315
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-14
- **Primary completion:** 2022-07-20
- **Final completion:** 2022-11-09
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04800315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04800315, "A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04800315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*